Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03667326
PHASE2

Postpartum Low-Dose Aspirin and Preeclampsia

Sponsor: Columbia University

View on ClinicalTrials.gov

Summary

The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.

Official title: Low-Dose Aspirin in the Postpartum Period and Endothelial Function in Patients With Preeclampsia

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2019-07-22

Completion Date

2026-12

Last Updated

2026-01-22

Healthy Volunteers

Yes

Interventions

DRUG

Aspirin tablet

Low dose aspirin, 81mg tablets, PO

DRUG

Placebo oral capsule

Placebo oral capsule, PO

Locations (1)

Columbia University Irving Medical Center

New York, New York, United States